Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday.
According to Zacks, “Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. “
LXRX has been the subject of a number of other research reports. BidaskClub lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, June 29th. ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. HC Wainwright set a $27.00 target price on Lexicon Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 3rd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $21.00 target price on shares of Lexicon Pharmaceuticals in a research note on Wednesday, April 5th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $26.67.
Shares of Lexicon Pharmaceuticals (NASDAQ LXRX) opened at 15.92 on Tuesday. Lexicon Pharmaceuticals has a 52 week low of $13.41 and a 52 week high of $19.62. The stock has a 50 day moving average price of $15.77 and a 200 day moving average price of $15.16. The firm’s market cap is $1.68 billion.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LXRX. C WorldWide Group Holding A S raised its position in Lexicon Pharmaceuticals by 2.5% in the first quarter. C WorldWide Group Holding A S now owns 11,677 shares of the biopharmaceutical company’s stock worth $167,000 after buying an additional 280 shares during the last quarter. 361 Capital LLC acquired a new position in Lexicon Pharmaceuticals during the first quarter worth approximately $186,000. Numeric Investors LLC acquired a new position in Lexicon Pharmaceuticals during the fourth quarter worth approximately $295,000. Trexquant Investment LP acquired a new position in Lexicon Pharmaceuticals during the first quarter worth approximately $323,000. Finally, Principal Financial Group Inc. raised its position in Lexicon Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 22,684 shares of the biopharmaceutical company’s stock worth $325,000 after buying an additional 70 shares during the last quarter.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.